Latest News
-
September 15, 2026Voronoi's VRN11 Confirms Differentiated Antitumor Effect in C797S Patients and Patients with Brain Metastases
-
September 14, 2026Voronoi Receives Thai Phase 1b/2 IND Approval for VRN11... Expands Global Clinical Trial
-
September 09, 2026Voronoi Receives Commendation from President of Korea Health Industry Development Institute... Recognized for Innovative Achievements in Global Open Innovation
-
September 08, 2026Voronoi Receives Malaysian Phase 1b/2 IND Approval for EGFR Targeted Therapy VRN11... Expands Global Clinical Trial
-
September 01, 2026Voronoi to Present VRN11 and VRN10 Data at WCLC 2026... Demonstrating Global Competitiveness
-
August 18, 2026Voronoi Receives Singapore IND Approval for Next-Generation Lung Cancer Targeted Therapy VRN11... Expands Global First-Line EGFR Lung Cancer Clinical Trial
-
August 07, 2026Voronoi Submits Canadian IND for VRN11... Launches North American Clinical Development in Earnest
-
August 03, 2026Voronoi Receives Hong Kong IND Approval for VRN11... Expands Global First-Line Treatment Clinical Trial
-
June 02, 2026Voronoi Announces Interim Phase 1a Results for Next-Generation HER2 Solid Tumor Therapy 'VRN10'...
Anticancer Activity Confirmed in Post-Enhertu Patients and Patients with Brain Metastases -
June 01, 2026Voronoi's Next-Generation Lung Cancer Targeted Therapy 'VRN11' Confirms Cases of Complete Tumor Disappearance in EGFR Patients with Brain Metastases
-
May 28, 2026Voronoi Receives Approval to Expand VRN11 Phase 1/2 Trial in Australia... Launches Clinical Trial in EGFR-Naive Patients in an Advanced Market
-
April 20, 2026Voronoi Releases 'VRN10' Clinical Data at AACR 2026... Presents New Possibilities for HER2 Treatment
-
April 20, 2026Voronoi's 'Next-Generation Lung Cancer Targeted Therapy VRN11' Records 100% Objective Response Rate in EGFR C797S-Resistant Patients
-
December 12, 2025Voronoi Releases 'VRN10' Phase 1 Data at SABCS 2025... "Antitumor Effect Confirmed from Initial Doses"
-
December 08, 2025Voronoi Demonstrates VRN11's Potential as a Next-Generation EGFR Lung Cancer Drug at ESMO Asia 2025
-
October 26, 2025Voronoi Releases Clinical Data on HER2-Targeting Therapy VRN10... Tumor Shrinkage Confirmed Without Side Effects from Initial Doses
-
October 24, 2025Voronoi Presents Clinical Data on Key Pipeline Programs at AACR-NCI-EORTC 2025
-
September 19, 2025Voronoi Successfully Transfers VRN04 Program... Signs Definitive Purchase Agreement
-
April 28, 2025Voronoi's VRN11 Demonstrates Efficacy at Low Dose in EGFR C797S Non-Small Cell Lung Cancer Patient with Brain Metastases
-
March 26, 2025Voronoi Receives Korean Phase 1 IND Approval for HER2-Positive Solid Tumor Therapy VRN10
-
February 10, 2025Voronoi to Present Early Clinical Data on VRN11 Ahead of Schedule at AACR 2025
-
November 29, 2024Voronoi Files Phase 1 IND Application for HER2-Positive Solid Tumor Therapy VRN10
-
August 26, 2024Voronoi Signs License-Out Option Agreement with U.S. Biotech ANVIA
-
July 04, 2023Voronoi's HER2-Positive Solid Tumor Therapy Selected for Korea Drug Development Fund Project
-
June 28, 2023Voronoi Files Phase 1 IND Application for Non-Small Cell Lung Cancer Therapy VRN11
-
June 19, 2023Voronoi's Largest Shareholder to Participate in Rights Offering with KRW 18 Billion
-
March 08, 2023Voronoi Merges Three Companies to 'Maximize Research Efficiency'
-
November 07, 2022Voronoi's Pulmonary Arterial Hypertension Therapy Selected for Korea Drug Development Fund Project
-
August 12, 2022Voronoi's Non-Small Cell Lung Cancer Therapy Selected for Korea Drug Development Fund Project
-
January 24, 2022Voronoi Files Securities Registration Statement for KOSDAQ Listing
-
November 23, 2021Voronoi, with 'KRW 2 Trillion in License-Out Deals,' Receives Minister of Health and Welfare Commendation
-
November 17, 2021Voronoi Licenses Out MPS1-Targeting Solid Tumor Therapy
-
September 01, 2021Voronoi Licenses Out Autoimmune Disease Therapy in KRW 380 Billion Deal
-
June 22, 2021Voronoi Passes Technology Evaluation
-
October 20, 2020Voronoi Licenses Out Lung Cancer Therapy to ORIC in the U.S. in KRW 720 Billion Deal